ChronoScale Holdings Corp IPO Filing Research

DRS filed

Draft registration statement

Draft registration filed confidentially before the public launch.

First tracked pre-IPO filing for this issuer.

2026-09-29 · 0001493152-26-044916

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows 424B5 and marks the registration effective.

2026-07-15 · 9999999995-26-002314

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows 424B5 and confirms the priced prospectus.

Price $4.81 · 769,490 shares · Gross proceeds $3,701,247

Common Stock · Exchange Nasdaq · Ticker EKSO · Placement Agent Warrant to purchase 15,389 shares at $4.81 · Use of proceeds for general corporate purposes · Underwriters Lake Street Capital Markets, LLC

2025-10-29 · 0001437749-25-032209

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows EFFECT and confirms the priced prospectus.

275,245 shares

Common Stock · Exchange Nasdaq · Ticker EKSO · Use of proceeds To terminate the continuous offering under the Prospectus

2025-10-28 · 0001437749-25-031976

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows 424B4 and marks the registration effective.

2025-04-17 · 9999999995-25-001141

424B4 priced

Final prospectus

Final prospectus filed after pricing with final deal terms.

Follows EFFECT and confirms the priced prospectus.

Price $1.00 · 3,100,000 shares · Gross proceeds $5,997,100

Series A Warrant to Purchase One Share of Common Stock and One Series B Warrant to Purchase One Share · Exchange Nasdaq · Ticker EKSO · One Share of Common Stock, One Series A Warrant, One Series B Warrant · Series A Warrant to purchase one share at $1.00 exercisable for 5 years; Series B Warrant to purchase one share at $1.00 exercisable for 1 year; Pre-Funded Warrant to purchase one share at $0.001 · Flags units, warrants · Underwriters Craig-Hallum

2024-08-30 · 0001437749-24-028168

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows S-1/A and marks the registration effective.

2024-08-29 · 9999999995-24-002684

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1 filing.

5,530,973 shares

Series A Warrant to Purchase One Share of Common Stock and One Series B Warrant to Purchase One Share · Exchange Nasdaq · Ticker EKSO · Each Unit Consisting of One Share of Common Stock (or One Pre-Funded Warrant to Purchase One Share of Common Stock in Lieu Thereof), One Series A Warrant to Purchase One Share of Common Stock and One Series B Warrant to Purchase One Share of Common Stock · Series A Warrant to purchase one share at $ per share, expiring in 5 years; Series B Warrant to purchase one share at $ per share, expiring in 1 year · Flags units, warrants · Underwriters Craig-Hallum

2024-08-28 · 0001437749-24-027894

S-1 filed

Initial registration statement

Initial public filing submitted to start the SEC review process.

Follows 424B5 in the pre-IPO sequence.

Shares of common stock and pre-funded warrants to purchase shares of common stock · Exchange Nasdaq · Ticker EKSO · Pre-funded warrants to purchase shares of common stock with exercise price of $0.001 per share · Use of proceeds Working capital · Flags warrants · Underwriters Craig-Hallum

2024-07-29 · 0001437749-24-023751

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows 424B5 and confirms the priced prospectus.

Price $1.55 · 2,967,742 shares · Gross proceeds $4,600,000

Common Stock · Exchange Nasdaq · Ticker EKSO · Underwriters A.G.P./Alliance Global Partners

2024-01-12 · 0001437749-24-001231

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows EFFECT and confirms the priced prospectus.

Gross proceeds $5,000,000

Common Stock · Exchange Nasdaq · Ticker EKSO · Underwriters H.C. Wainwright & Co., LLC

2023-07-28 · 0001437749-23-020965

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows 424B5 and marks the registration effective.

2023-06-20 · 9999999995-23-001803

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows FWP and confirms the priced prospectus.

Price $10.25 · 3,902,440 shares · Gross proceeds $40,000,010

Common Stock · Exchange NASDAQ · Ticker EKSO · Over-allotment 585,366 · Use of proceeds working capital, and for other general corporate purposes · Underwriters H.C. Wainwright & Co.

2021-02-10 · 0001104659-21-019792

FWP supplemental

Free writing prospectus

Prospectus supplement or marketing filing that often updates active offering terms.

Follows FWP and supplements the active offering with updated prospectus details.

Price $10.25 · 3,902,440 shares · Gross proceeds $40,000,000

Common Stock · Exchange Nasdaq · Ticker EKSO · Over-allotment 585,366 · Use of proceeds for working capital, debt repayment, acquisitions, and other general corporate purposes · Underwriters H.C. Wainwright & Co.

2021-02-09 · 0001104659-21-016263

FWP supplemental

Free writing prospectus

Prospectus supplement or marketing filing that often updates active offering terms.

Follows 424B5 and supplements the active offering with updated prospectus details.

Price $10.25 · 975,610 shares · Gross proceeds $10,000,000

Common · Exchange NASDAQ · Ticker EKSO · Over-allotment 146,341 · Use of proceeds Working capital and general corporate purposes, including debt repayment and acquisitions · Underwriters H.C. Wainwright & Co., LLC

2021-02-08 · 0001104659-21-014304

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows 424B5 and confirms the priced prospectus.

Exchange Nasdaq Capital Market · Ticker EKSO · Underwriter receives warrants to purchase 7% of shares issued · Underwriters H.C. Wainwright & Co.

2021-02-08 · 0001104659-21-014298

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows EFFECT and confirms the priced prospectus.

Common Stock · Exchange Nasdaq Capital Market · Ticker EKSO · Use of proceeds General corporate purposes · Underwriters H.C. Wainwright & Co., LLC

2020-10-09 · 0001549084-20-000031

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows 424B1 and marks the registration effective.

2020-07-13 · 9999999995-20-001792

424B1 priced

Final prospectus

Final prospectus filed after pricing with final deal terms.

Follows S-1 and confirms the priced prospectus.

873,852 shares · Gross proceeds $4,500,000

Common Stock · Exchange Nasdaq Capital Market · Ticker EKSO · Warrants issued on June 10, 2020, exercisable at $5.18 per share, totaling 873,852 shares · Selling stockholders only · Use of proceeds Proceeds from warrant exercises will be used for general corporate purposes

2020-07-13 · 0001104659-20-083033

S-1 filed

Initial registration statement

Initial public filing submitted to start the SEC review process.

Follows EFFECT in the pre-IPO sequence.

Price $6.91 · 873,852 shares · Gross proceeds $6,038,317

Common Stock, $0.001 par value per share · Exchange NASDAQ · Ticker CHRS · June 2020 Warrants · Selling stockholders only · Use of proceeds Proceeds from the sale of shares by selling stockholders, with no proceeds to the issuer.

2020-07-02 · 0001104659-20-080674

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows 424B5 and marks the registration effective.

2020-06-26 · 9999999995-20-001693

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows 424B5 and confirms the priced prospectus.

1,114,494 shares · Gross proceeds $10,756,633

Common Stock · Exchange Nasdaq Capital Market · Ticker EKSO · Warrants to purchase common stock with exercise prices ranging from $3.52 to $41.25 and expiration dates from 2020 to 2025 · Use of proceeds Proceeds from warrant exercises will be used for general corporate purposes

2020-06-26 · 0001104659-20-077477

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows 424B3 and confirms the priced prospectus.

Price $4.51 · 1,747,704 shares · Gross proceeds $7,890,010

Common Stock · Exchange Nasdaq Capital Market · Ticker EKSO · Warrants to purchase 873,852 shares at $5.18 exercise price, exercisable immediately, 5.5-year term · Underwriters H.C. Wainwright & Co., LLC

2020-06-09 · 0001104659-20-071471

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows 424B5 and confirms the priced prospectus.

Warrants to Purchase Shares of Common Stock · Exchange NASDAQ · Warrants exercisable at $0.38 per share after adjustment

2019-12-30 · 0001104659-19-076562

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows 424B5 and confirms the priced prospectus.

Price $0.45 · 11,111,116 shares · Gross proceeds $5,000,002

Common Stock, $0.001 par value · Exchange Nasdaq · Ticker EKSO · Investor Warrants to purchase 8,333,337 shares and Placement Agent Warrants to purchase 777,778 shares · Use of proceeds general corporate purposes · Flags warrants · Underwriters H.C. Wainwright & Co., LLC

2019-12-20 · 0001104659-19-074701

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows 424B5 and confirms the priced prospectus.

Price $1.50 · 6,666,667 shares · Gross proceeds $10,000,001

warrant to purchase one share of our common stock accompanying each share · Exchange NASDAQ · Ticker EKSO · Warrants to purchase 6,666,667 shares of common stock at $2.00 per share · Flags warrants · Underwriters Cantor, SunTrust Robinson Humphrey

2019-05-24 · 0001144204-19-028070

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows 424B3 and confirms the priced prospectus.

warrant to purchase one share of our common stock accompanying each share · Exchange Nasdaq · Ticker EKSO · One share of common stock and one warrant to purchase one share of common stock · Warrants to purchase shares of common stock at an exercise price of [unknown], exercisable upon issuance, expiring five years from issuance, with a 4.99% ownership limit · Flags units, warrants · Underwriters Cantor, SunTrust Robinson Humphrey

2019-05-21 · 0001144204-19-027501

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows 424B5 and confirms the priced prospectus.

Price $2.75 · 1,603,442 shares · Gross proceeds $4,400,000

Common Stock Underlying Warrants · Exchange Nasdaq Capital Market · Ticker EKSO · Warrants to purchase 1,603,442 shares of common stock at $2.75 per share · Use of proceeds Proceeds from warrant exercises

2019-03-13 · 0001144204-19-013730

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows 424B5 and confirms the priced prospectus.

Gross proceeds $25,000,000

Common Stock · Exchange Nasdaq Capital Market · Ticker EKSO · Underwriters Cantor Fitzgerald & Co.

2018-08-21 · 0001144204-18-045682

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows 424B1 and confirms the priced prospectus.

Price $3.74 · 1,603,442 shares · Gross proceeds $5,996,873

Warrants to Purchase Shares of Common Stock · Exchange Nasdaq Capital Market · Ticker EKSO · Warrants to Purchase Shares of Common Stock · Warrants exercisable at $3.74 per share for 1,603,442 shares of common stock · Use of proceeds Proceeds from warrant exercises will be used for general corporate purposes

2018-07-10 · 0001144204-18-037758

424B1 priced

Final prospectus

Final prospectus filed after pricing with final deal terms.

Follows EFFECT and confirms the priced prospectus.

20,534,898 shares

Common Stock · Exchange Nasdaq · Ticker EKSO · Selling stockholders only · Use of proceeds Selling stockholders are selling shares, and the company will not receive any proceeds

2017-10-19 · 0001144204-17-053242

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows FWP and marks the registration effective.

2017-10-18 · 9999999995-17-002717

FWP supplemental

Free writing prospectus

Prospectus supplement or marketing filing that often updates active offering terms.

Follows 424B2 and supplements the active offering with updated prospectus details.

Price $1.00

subscription right for each share · Exchange NASDAQ · Ticker EKSO · Use of proceeds for clinical, sales and marketing initiatives, research, development, and working capital

2017-08-28 · 0000919574-17-006422

424B2 filed

Prospectus supplement

Prospectus supplement that can carry timing details without itself confirming imminent trading.

Follows EFFECT in the pre-IPO sequence.

Price $1.00 · 34,000,000 shares · Gross proceeds $34,000,000

subscription right for each common share · Exchange Nasdaq Capital Market · Ticker EKSO · Use of proceeds Net proceeds to the company are $33,665,000

2017-08-14 · 0000919574-17-006026

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows 424B5 and marks the registration effective.

2017-06-16 · 9999999995-17-001573

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows 424B5 and confirms the priced prospectus.

Price $3.14 · 3,732,356 shares · Gross proceeds $11,719,598

Common Stock · Exchange Nasdaq · Ticker EKSO · Warrants to purchase 1,866,178 shares of common stock, with 0.5 warrants per share · Flags warrants

2017-04-05 · 0001144204-17-018970

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows 8-A12B and confirms the priced prospectus.

Price $4.00 · 3,750,000 shares · Gross proceeds $15,000,000

Common Stock · Exchange NASDAQ · Ticker EKSO · Over-allotment 562,500 · Use of proceeds To fund operations and general corporate purposes · Underwriters Cowen and Company, SunTrust Robinson Humphrey, B. Riley & Co.

2016-08-09 · 0001144204-16-117746

8-A12B effective

Exchange Act registration

Registration filed to list the securities under the Exchange Act ahead of trading.

Follows 424B5 and registers the class of securities for exchange listing.

2016-08-08 · 0001144204-16-117247

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows EFFECT and confirms the priced prospectus.

Common Stock · Exchange OTC · Ticker EKSO · Underwriters Cowen and Company

2016-08-08 · 0001144204-16-117206

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows 424B3 and marks the registration effective.

2016-04-15 · 9999999995-16-004228

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows 424B3 and confirms the priced prospectus.

67,134,768 shares

Common Stock · 13,125,800 shares issuable upon exercise of common stock purchase warrants · Selling stockholders only · Use of proceeds Proceeds will be received by selling stockholders, with no proceeds to the issuer

2016-03-01 · 0001144204-16-085285

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows 424B3 and confirms the priced prospectus.

67,134,768 shares

Common Stock · Exchange NASDAQ · Ticker EKSO · 13,125,800 shares issuable upon exercise of common stock purchase warrants · Selling stockholders only · Use of proceeds Proceeds will go to selling stockholders

2015-12-29 · 0001144204-15-073025

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows 424B5 and confirms the priced prospectus.

67,134,768 shares

Common Stock · Common stock purchase warrants · Selling stockholders only · Use of proceeds Selling stockholders are offering shares, and the company will not receive any proceeds.

2015-12-24 · 0001144204-15-072708

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows 424B3 and confirms the priced prospectus.

Price $1,000 · 15,000 shares · Gross proceeds $15,000,000

Series A Convertible Preferred Stock and Warrant to Purchase 990.1 Shares of Common Stock · Exchange OTC Markets · Ticker EKSO · Each unit consists of one share of Series A Preferred Stock and a warrant to purchase approximately 990 shares of common stock · Warrants to purchase up to 14,851,486 shares of common stock at $1.25 exercise price · Use of proceeds Working capital · Flags units, warrants · Underwriters LADENBURG THALMANN, TROUT CAPITAL

2015-12-24 · 0001144204-15-072706

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows 424B3 and confirms the priced prospectus.

67,134,768 shares

Common · Ticker EKSO · 13,125,800 shares issuable upon exercise of common stock purchase warrants · Selling stockholders only · Use of proceeds Selling stockholders' shares; no issuer proceeds

2015-12-04 · 0001144204-15-069292

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows 424B3 and confirms the priced prospectus.

67,134,768 shares

Common · 13,125,800 shares issuable upon exercise of common stock purchase warrants · Selling stockholders only · Use of proceeds Proceeds will be received by the selling stockholders, with no proceeds to the company

2015-11-10 · 0001144204-15-064071

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows 424B3 and confirms the priced prospectus.

67,134,768 shares · Gross proceeds $0.00

Common Stock · 13,125,800 shares issuable upon exercise of common stock purchase warrants · Selling stockholders only · Use of proceeds Proceeds will be received by selling stockholders, with no proceeds to the issuer

2015-09-14 · 0001144204-15-054813

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows EFFECT and confirms the priced prospectus.

67,134,768 shares

Common Stock, par value $0.001 per share · Ticker EKSO · 13,125,800 issuable upon exercise of common stock purchase warrants · Selling stockholders only · Use of proceeds Proceeds from the resale of shares by selling stockholders, with no proceeds to the issuer. · Flags warrants

2015-08-13 · 0001144204-15-048733

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows 424B3 and marks the registration effective.

2015-07-09 · 9999999995-15-001873

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows 424B3 and confirms the priced prospectus.

67,134,768 shares

Common Stock · 13,141,800 shares issuable upon exercise of common stock purchase warrants · Selling stockholders only · Use of proceeds Proceeds will be received by selling stockholders, with no proceeds to the issuer

2015-05-12 · 0001144204-15-029511

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows 424B3 and confirms the priced prospectus.

67,134,768 shares

Common Stock · Ticker EKSO · 13,141,800 shares issuable upon exercise of common stock purchase warrants · Selling stockholders only · Use of proceeds Selling stockholders are offering shares, with no proceeds going to the issuer

2015-04-23 · 0001144204-15-024471

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows EFFECT and confirms the priced prospectus.

Price $1.29 · 67,134,768 shares

Common Stock · Exchange OTC Markets · Ticker EKSO · 13,141,800 issuable upon exercise of common stock purchase warrants · Selling stockholders only · Use of proceeds selling stockholders with no issuer proceeds

2015-04-06 · 0001144204-15-021296

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows 424B3 and marks the registration effective.

2015-04-03 · 9999999995-15-000780

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows 424B3 and confirms the priced prospectus.

67,134,768 shares

Common Stock · Warrants to purchase 600,000 shares of common stock · Selling stockholders only · Use of proceeds Proceeds will go to the selling stockholders, with no proceeds to the company

2015-02-05 · 0001144204-15-006015

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows 424B3 and confirms the priced prospectus.

67,134,768 shares

Common Stock · Warrants to purchase common stock issued to selling stockholders · Selling stockholders only · Use of proceeds Proceeds will be received by selling stockholders, with no proceeds to the issuer · Flags warrants

2015-01-26 · 0001144204-15-003682

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows 424B3 and confirms the priced prospectus.

67,134,768 shares

Common Stock · Warrants exercisable at $1.00 per share, with 13,174,500 shares issuable upon exercise · Selling stockholders only · Use of proceeds Selling stockholders' shares; no proceeds to the issuer

2014-11-24 · 0001144204-14-070593

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows 424B3 and confirms the priced prospectus.

67,134,768 shares

Common Stock · Exchange NASDAQ · Ticker EKSO · 36,055,000 shares issuable upon exercise of common stock purchase warrants · Selling stockholders only · Use of proceeds Selling stockholders are reselling shares; no proceeds go to the issuer

2014-11-20 · 0001144204-14-070161

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows 424B3 and confirms the priced prospectus.

67,134,768 shares

Common · 36,055,000 shares issuable upon exercise of common stock purchase warrants · Selling stockholders only · Use of proceeds Proceeds will be received by selling stockholders

2014-11-10 · 0001144204-14-066162

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows 424B1 and confirms the priced prospectus.

67,134,768 shares

Common · 36,055,000 shares issuable upon exercise of common stock purchase warrants · Selling stockholders only · Use of proceeds Proceeds from selling stockholders' shares

2014-09-10 · 0001144204-14-055126

424B1 priced

Final prospectus

Final prospectus filed after pricing with final deal terms.

Follows EFFECT and confirms the priced prospectus.

67,134,768 shares

Common Stock · Exchange OTC Markets · Ticker EKSO · Warrants exercisable for 36,055,000 shares · Selling stockholders only · Use of proceeds Selling stockholders will receive all proceeds

2014-06-24 · 0001144204-14-039369

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows S-1/A and marks the registration effective.

2014-06-20 · 9999999995-14-001854

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1/A filing.

Price $2.70 · 67,134,768 shares · Gross proceeds $0.00

Common Stock, par value $0.001 per share · Exchange OTC Markets · Ticker EKSO · 36,055,000 shares issuable upon exercise of common stock purchase warrants · Selling stockholders only · Use of proceeds Selling stockholders will sell shares, no issuer proceeds · Flags self_underwritten · Underwriters self-underwritten

2014-06-09 · 0001144204-14-036518

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1 filing.

Price $2.70 · 67,134,768 shares · Gross proceeds $180,928,200

Common stock, par value $0.001 per share · Ticker EKSO · 36,055,000 shares of common stock issuable upon exercise of common stock purchase warrants · Use of proceeds Working capital · Flags warrants · Underwriters Gottbetter Capital Markets, LLC

2014-05-09 · 0001144204-14-029107

S-1 filed

Initial registration statement

Initial public filing submitted to start the SEC review process.

Follows EFFECT in the pre-IPO sequence.

Price $2.70 · 67,134,768 shares

Common Stock · Exchange OTC · Ticker EKSO · 36,055,000 shares issuable upon exercise of common stock purchase warrants · Selling stockholders only · Use of proceeds Selling stockholders will receive all proceeds from the sale of the shares

2014-05-07 · 0001144204-14-028321

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows S-1/A and marks the registration effective.

2012-08-06 · 9999999995-12-002388

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1/A filing.

Price $0.02 · 5,000,000 shares · Gross proceeds $100,000

Common Stock · Ticker PNMG · Use of proceeds Proceeds will be retained by the company

2012-07-19 · 0001165527-12-000768

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1/A filing.

Price $0.02 · 5,000,000 shares · Gross proceeds $100,000

Common Stock of PN Med Group Inc.

2012-07-11 · 0001165527-12-000721

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1/A filing.

Price $0.02 · 5,000,000 shares · Gross proceeds $100,000

Common Stock of PN Med Group Inc. · Use of proceeds Proceeds will be used for general corporate purposes. · Underwriters self-underwritten

ChronoScale Holdings Corp, a development-stage company, is seeking to raise up to $100,000 through a self-underwritten offering to fund operations, including medical supply purchases, office setup, advertising, and web development. The company has no revenue, relies on informal funding from its president, Pedro Niklitschek, and faces significant risks including a 'going concern' opinion, lack of market liquidity, and unproven business operations. The offering is structured with dilution disclosures and no minimum funding requirement.

2012-07-02 · 0001165527-12-000698

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1/A filing.

Price $0.02 · 5,000,000 shares · Gross proceeds $100,000

Common · Use of proceeds general corporate purposes

ChronoScale Holdings Corp is a development-stage company with no revenue, seeking to raise up to $100,000 through a self-underwritten offering. The offering is structured without a minimum share requirement, with proceeds allocated to operational costs, supplies, and marketing. The company faces significant risks including lack of operating history, reliance on a single executive, and potential delisting from OTCBB. The president, Mr. Niklitschek, will hold 50% of shares post-offering, maintaining control. The company has no revenue, limited assets, and a going concern opinion from auditors.

2012-06-15 · 0001165527-12-000648

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1 filing.

Price $0.02 · Range $0.02 to $0.02 · 5,000,000 shares · Gross proceeds $100,000

Common Stock · Use of proceeds Proceeds will be used for general corporate purposes. · Underwriters self-underwritten

ChronoScale Holdings Corp's S-1/A filing details PN Med Group Inc., a development-stage company incorporated in Nevada on 2012-01-30. The company plans to distribute medical supplies in Chile but has no revenue, $8,443 in cash, and $4,657 in losses. Financial statements show limited working capital, reliance on shareholder loans, and a going concern uncertainty. The filing includes audited financials, prospectus delivery obligations, and Part II information not present in the previous S-1.

2012-06-04 · 0001165527-12-000594

S-1 filed

Initial registration statement

Initial public filing submitted to start the SEC review process.

First tracked pre-IPO filing for this issuer.

Price $0.02 · 5,000,000 shares · Gross proceeds $100,000

Common Stock · Use of proceeds to develop business operations · Flags foreign_private_issuer

ChronoScale Holdings Corp, previously known as PN Med Group Inc., is a development-stage company incorporated in Nevada in January 2012. The company plans to distribute medical supplies and equipment in Chile but has no revenue, a net loss of $4,657, and limited working capital. Its financial statements raise substantial doubt about its ability to continue as a going concern due to operating losses, lack of revenue, and reliance on shareholder loans. The audit highlights risks related to liquidity, tax loss carryforwards, and unproven business operations.

2012-05-08 · 0001165527-12-000410

ChronoScale Holdings Corp

Filing Timeline

1 comparable deal

Recent News